Literature DB >> 1896455

Stimulation of glycoprotein gp120 dissociation from the envelope glycoprotein complex of human immunodeficiency virus type 1 by soluble CD4 and CD4 peptide derivatives: implications for the role of the complementarity-determining region 3-like region in membrane fusion.

E A Berger1, J D Lifson, L E Eiden.   

Abstract

We have used a recombinant vaccinia virus vector encoding the envelope glycoprotein of human immunodeficiency virus type 1 to study receptor-induced structural changes related to membrane fusion. A truncated soluble form of human CD4 (sCD4) was found to stimulate dissociation of the external subunit (gp120) from the envelope glycoprotein complex of human immunodeficiency virus type 1 expressed at the cell surface. sCD4 stimulation of gp120 release was time- and concentration-dependent and was associated with specific binding of sCD4 to gp120. Synthetic peptide derivatives corresponding to residues 81-92 of human CD4 (overlapping the complementarity-determining region 3-like region) inhibited cell-cell fusion mediated by the interaction between recombinant vaccinia-encoded CD4 and human immunodeficiency virus envelope glycoprotein. These peptide derivatives also stimulated gp120 release from the envelope glycoprotein complex. An analogous peptide derivative from chimpanzee CD4 (containing a single Glu----Gly substitution at the position corresponding to CD4 residue 87) was considerably less active at inhibition of cell-cell fusion and stimulation of gp120 release, consistent with the known inhibitory effect of this substitution on the ability of membrane-associated CD4 to mediate cell fusion. These results suggest that the sCD4-induced release of gp120 reflects postbinding structural changes in the envelope glycoprotein complex involved in membrane fusion, with the complementarity-determining region 3-like region playing a critical role.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1896455      PMCID: PMC52450          DOI: 10.1073/pnas.88.18.8082

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  46 in total

1.  Induction of CD4-dependent cell fusion by the HTLV-III/LAV envelope glycoprotein.

Authors:  J D Lifson; M B Feinberg; G R Reyes; L Rabin; B Banapour; S Chakrabarti; B Moss; F Wong-Staal; K S Steimer; E G Engleman
Journal:  Nature       Date:  1986 Oct 23-29       Impact factor: 49.962

2.  Substitution of murine for human CD4 residues identifies amino acids critical for HIV-gp120 binding.

Authors:  L K Clayton; R E Hussey; R Steinbrich; H Ramachandran; Y Husain; E L Reinherz
Journal:  Nature       Date:  1988-09-22       Impact factor: 49.962

3.  Genetic analysis of monoclonal antibody and HIV binding sites on the human lymphocyte antigen CD4.

Authors:  A Peterson; B Seed
Journal:  Cell       Date:  1988-07-01       Impact factor: 41.582

4.  Synthetic CD4 peptide derivatives that inhibit HIV infection and cytopathicity.

Authors:  J D Lifson; K M Hwang; P L Nara; B Fraser; M Padgett; N M Dunlop; L E Eiden
Journal:  Science       Date:  1988-08-05       Impact factor: 47.728

5.  Binding region for human immunodeficiency virus (HIV) and epitopes for HIV-blocking monoclonal antibodies of the CD4 molecule defined by site-directed mutagenesis.

Authors:  T Mizukami; T R Fuerst; E A Berger; B Moss
Journal:  Proc Natl Acad Sci U S A       Date:  1988-12       Impact factor: 11.205

6.  Improved antigenicity of the HIV env protein by cleavage site removal.

Authors:  M P Kieny; R Lathe; Y Rivière; K Dott; D Schmitt; M Girard; L Montagnier; J Lecocq
Journal:  Protein Eng       Date:  1988-09

7.  Expression of AIDS virus envelope gene in recombinant vaccinia viruses.

Authors:  S L Hu; S G Kosowski; J M Dalrymple
Journal:  Nature       Date:  1986 Apr 10-16       Impact factor: 49.962

8.  Expression of the HTLV-III envelope gene by a recombinant vaccinia virus.

Authors:  S Chakrabarti; M Robert-Guroff; F Wong-Staal; R C Gallo; B Moss
Journal:  Nature       Date:  1986 Apr 10-16       Impact factor: 49.962

9.  A region in domain 1 of CD4 distinct from the primary gp120 binding site is involved in HIV infection and virus-mediated fusion.

Authors:  A Truneh; D Buck; D R Cassatt; R Juszczak; S Kassis; S E Ryu; D Healey; R Sweet; Q Sattentau
Journal:  J Biol Chem       Date:  1991-03-25       Impact factor: 5.157

10.  pH-independent HIV entry into CD4-positive T cells via virus envelope fusion to the plasma membrane.

Authors:  B S Stein; S D Gowda; J D Lifson; R C Penhallow; K G Bensch; E G Engleman
Journal:  Cell       Date:  1987-06-05       Impact factor: 41.582

View more
  34 in total

1.  Soluble receptor-induced retroviral infection of receptor-deficient cells.

Authors:  R Damico; P Bates
Journal:  J Virol       Date:  2000-07       Impact factor: 5.103

2.  Substitutions in the receptor-binding domain of the avian sarcoma and leukosis virus envelope uncouple receptor-triggered structural rearrangements in the surface and transmembrane subunits.

Authors:  R Damico; L Rong; P Bates
Journal:  J Virol       Date:  1999-04       Impact factor: 5.103

3.  Three-dimensional structures of soluble CD4-bound states of trimeric simian immunodeficiency virus envelope glycoproteins determined by using cryo-electron tomography.

Authors:  Tommi A White; Alberto Bartesaghi; Mario J Borgnia; M Jason V de la Cruz; Rachna Nandwani; James A Hoxie; Julian W Bess; Jeffrey D Lifson; Jacqueline L S Milne; Sriram Subramaniam
Journal:  J Virol       Date:  2011-09-21       Impact factor: 5.103

4.  The appealing story of HIV entry inhibitors : from discovery of biological mechanisms to drug development.

Authors:  Antonella Castagna; Priscilla Biswas; Alberto Beretta; Adriano Lazzarin
Journal:  Drugs       Date:  2005       Impact factor: 9.546

5.  Kinetics of soluble CD4 binding to cells expressing human immunodeficiency virus type 1 envelope glycoprotein.

Authors:  D S Dimitrov; K Hillman; J Manischewitz; R Blumenthal; H Golding
Journal:  J Virol       Date:  1992-01       Impact factor: 5.103

6.  A monoclonal antibody to the CDR-3 region of CD4 inhibits soluble CD4 binding to virions of human immunodeficiency virus type 1.

Authors:  J P Moore
Journal:  J Virol       Date:  1993-06       Impact factor: 5.103

7.  Association of T cell and macrophage dysfunction with surface gp 120-immunoglobulin-complement complexes in HIV-infected patients.

Authors:  V Daniel; C Süsal; R Weimer; R Zimmermann; A Huth-Kühne; G Opelz
Journal:  Clin Exp Immunol       Date:  1993-08       Impact factor: 4.330

8.  gp120-independent fusion mediated by the human immunodeficiency virus type 1 gp41 envelope glycoprotein: a reassessment.

Authors:  L Marcon; J Sodroski
Journal:  J Virol       Date:  1994-03       Impact factor: 5.103

9.  Enhanced in vitro human immunodeficiency virus type 1 replication in B cells expressing surface antibody to the TM Env protein.

Authors:  Y Tani; E Donoghue; S Sharpe; E Boone; H C Lane; S Zolla-Pazner; D I Cohen
Journal:  J Virol       Date:  1994-03       Impact factor: 5.103

10.  Human immunodeficiency virus type 1 envelope glycoprotein molecules containing membrane fusion-impairing mutations in the V3 region efficiently undergo soluble CD4-stimulated gp120 release.

Authors:  E A Berger; J R Sisler; P L Earl
Journal:  J Virol       Date:  1992-10       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.